MedPharm to Expand its UK Analytical Service Labs

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter 06-02-2021
Volume 16
Issue 6

MedPharm’s £1.5-million (US$2.1-million) expansion of its Surrey, United Kingdom, facility will increase its UK laboratory space by 35% and enhance its topical and transdermal services.

MedPharm, a formulation development and analytical services company for topical and transdermal products, has invested £1.5 million (US$2.1 million) into the refurbishment and expansion of its 15,000-ft2 facility in Surrey, United Kingdom, increasing its UK laboratory space by 35%.

The expansion, which is set to be completed by the fourth quarter of 2021, will allow for a more efficient workflow and the ability for the company to continue to meet the demand for topical and transdermal services, MedPharm said in a May 20, 2021 company press release.

“We are excited to be renovating our formulation development and analytical laboratories, clinical manufacturing suites, and personnel workspace to ensure our operations and capabilities remain state of the art,” said Rob Turner, general manager UK, MedPharm, in the press release. “During the renovations, we will take extensive steps to de-risk the process and do not expect any disruption to our existing services, quality of scientific deliverables, and client commitments throughout the refurbishment.”

Source: MedPharm

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content